Advaxis Launches MINE(TM) Collaboration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Advaxis (ADXS) Launches MINE Collaboration with MSK Cancer Center
October 27, 2015 9:04 AM EDTAdvaxis (NASDAQ: ADXS) announced the launch of a research collaboration with Memorial Sloan Kettering Cancer Center (MSK), a premier cancer center committed to patient care and innovative research, to evaluate the immunologic and anti-tumor activity of patient tumor-specific, neoepitope-based immunotherapy.
The goal of the collaboration, titled MINE (My Immunotherapy Neo-Epitopes), is to use Advaxiss Lm Technology to develop neo-epitope immunotherapies based on an individual patients tumor (ADXS-NEO). MINE will first focus on a preclinical study of Advaxiss new construct approach to evaluate the immunologic... More
